Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

Texas MPN Workshop 2021 | Potential approval of pacritinib for the treatment of myelofibrosis

Aaron Gerds • 11 Aug 2021
Texas MPN Workshop 2021
Myelofibrosis Myeloproliferative Neoplasms Pacritinib
PERSIST-2

Aaron Gerds, MD, Cleveland Clinic, Cleveland, OH, discusses the rolling submission of a New Drug Application for the tyrosine kinase inhibitor pacritinib and outlines the impacts this potential approval could have on the treatment of patients with myelofibrosis. Dr Gerds talks on the Phase III PERSIST-2 (NCT02055781) trial which has demonstrated that pacritinib can be delivered safely in thrombocytopenic patients, a patient subgroup whose clinical needs have not been adequately served by ruxolitinib or other currently available agents. This interview took place at the Texas MPN Workshop: Second Annual Workshop and Meeting in 2021.

More from Aaron Gerds

1:27
Real-world use of fedratinib in patients with MF who have failed on ruxolitinib
Aaron Gerds • 6 Dec 2023
1:56
Treating elderly, non-transplant eligible patients with MF
Aaron Gerds • 6 Dec 2023
2:39
The MOST study: differences in disease progression amongst patients with low-risk MF
Aaron Gerds • 6 Dec 2023
1:30
XPORT-MF-044 trial: evaluating selinexor in JAK inhibitor-naïve MF and moderate thrombocytopenia
Aaron Gerds • 6 Dec 2023

Related Videos

2:05
Donor lymphocyte infusion for relapsed myelofibrosis in the post-alloSCT setting
Alex Rampotas • 16 Apr 2024
2:52
JAK inhibitor combination therapy for the treatment of myelofibrosis
Ruben Mesa • 9 Dec 2023
1:30
XPORT-MF-034: selinexor + ruxolitinib combination therapy for MF
John Mascarenhas • 10 Dec 2023
1:38
Pelabresib plus ruxolitinib for the treatment of intermediate- and high-risk myelofibrosis
John Mascarenhas • 10 Dec 2023
The content of VJHemOnc is intended for healthcare professionals